Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox (Mpox) Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Pemphigus vulgaris (PV)
- Natural course of pemphigus
- Prognosis of pemphigus
- Clinical & pathological correlations of pemphigus
- Pemphigus vulgaris: visual examples
- Acantholysis
- HE staining of pemphigus vulgaris
- Early acantholysis
- Late acantholysis
- Pemphigus foliaceus (PF) (1)
- Pemphigus foliaceus (PF) (2)
- Direct immunofluorescence
- Indirect immunofluorescence (1)
- Indirect immunofluorescence (2)
- Skin Abs in pemphigus vulgaris
- Mechanical signs of pemphigus acantholysis
- Nikolskiy sign
- Piotr Vasiliyevich Nikolskiy (1)
- Piotr Vasiliyevich Nikolskiy (2)
- Marginal Nikolskiy sign
- Direct Nikolskiy sign
- Positive Nikolskiy sign on oral mucosa
- Clinical significance of Nikolskiy sign
- Epidermal peeling
- Intraepidermal split vs. epidermal peeling
- Epidermal peeling due to necrosis
- Pear sign (1)
- Pear sign (2)
- Blister-spread sign (Asboe-Hansen-Lutz)
- Blister spread sign
- Summary: positive\negative Nikolskiy sign
- Mechanical symptoms in blistering dermatoses
- Pemphigus and neoplasia
- Concurrent malignancies (1)
- Paraneoplastic pemphigus
- Paraneoplastic vs. classical pemphigus
- Vulgaris vs. PAMS: skin lesions (1)
- Vulgaris vs. PAMS: skin lesions (2)
- Vulgaris vs. PAMS: mucosal lesions (1)
- Vulgaris vs. PAMS: mucosal lesions (2)
- Vulgaris vs. PAMS: mucocutaneous lesions (1)
- Vulgaris vs. PAMS: mucocutaneous lesions (2)
- Direct immunofluorescence in PAMS
- Vulgaris vs. PAMS: organ involvement (1)
- Vulgaris vs. PAMS: organ involvement (2)
- Respiratory problems in PAMS
- Mechanisms of the epithelial variant of PAMS
- Antigen specificities of pathogenic Abs in PV
- Autoantibodies in pemphigus
- Dr. Amigai and Dr. Stanley
- Dsg 1&3 Abs and disease phenotype
- Ab titers and disease severity
- PF & PV and Dsg 1&3 antibodies (1)
- Abs absorption by PV antigen Dsg3
- rDsg3-Ig absorption of all disease-causing Abs
- Producing rDsg3 & rDsg3-Ig proteins
- PV IgGs absorbed by recombinant Dsg 1 & Dsg 3
- New targets of PV Abs with protein array
- PF & PV and Dsg 1&3 antibodies (2)
- Dsg 1&3 and epidermal integrity (1)
- Desmoglein compensation theory
- Dsg 3 does not compensate for Dsc 3 loss
- Autoimmunity to Dsc3 in PV
- Dsg 1&3 and epidermal integrity (2)
- Steric hindrance of Dsg 3 (1)
- Dsg3 is not essential for acantholysis
- Signaling dependent & independent mechanisms
- Steric hindrance of Dsg 3 (2)
- Autoimmune pemphigus: sera Abs (1)
- Pemphigus autoantibody profile by IP
- Dsg 1&3: in spotlight, others are awaiting
- PV autoantibody profiling by proteomic technique
- Proteomic study of PV antibodies (1)
- Proteomic study of PV antibodies (2)
- Sensitivity test: top 25 antigens
- Combination of top 10 antigens (by frequency)
- Proteomic study of PV antibodies (3)
- Specificity test: top 25 antigens
- Combination of top 10 antigens (by ratio)
- Autoimmune pemphigus: sera Abs (2)
- Acantholysis & desmosomes
- Desmosomes are preserved in early acantholysis
- Steric hindrance of Dsg 3 (3)
- The role of desmoglein autoantibodies in PV
- Hypothetical mechanism of Ab production in PV
- Pathogenic significance of mitochondrial Abs
- Mitochondrial damage by PV antibodies
- Abs against keratinocyte mitochondrial proteins
- PV sera effects: mitochondrial O2 respiration
- PV sera effects: mitochondrial membrane potential
- PV sera effects: ROS production in keratinocytes
- Alterations of mitochondrial functions by PV IgG
- Drugs affecting mitochondrial stability & functions
- Mitochondria-protecting drugs
- Mitochondria-protecting drugs: clinical significance
- Summary of mitochondrial damage in PV
- Non IgG acantholytic factors in PV
- Acantholysis in EpiDerm tissue
- Current understanding of pathophysiology of PV
- Keratinocyte detachment & blister formation in PV
- The basal cell shrinkage hypothesis in PV
- Signs of apoptosis in PV: major references
- Activation of caspases and calpains by PV IgG
- Apoptotic keratinocytes in pemphigus lesions
- Acantholysis and apoptosis are inseparable in PV
- Apoptolysis: Apoptosis + Acantholysis
- Apoptolysis: a novel mechanism of skin blistering
- Apoptolysis: stages
- Treatment of pemphigus
- Local treatment of pemphigus lesions
- Unnecessary aggressive debridement: results
- Systemic treatment of pemphigus (1)
- Systemic treatment of pemphigus (2)
- Important facts regarding corticosteroids (1)
- Important facts regarding corticosteroids (2)
- PV IgG vs. methylprednisolone
- Adverse effects of corticosteroid therapy
- Immunosuppression with cytotoxic drugs
- Immunosuppression with immunomodulators (1)
- Immunosuppression with immunomodulators (2)
- Immunosuppression with immunomodulators (3)
- Immunosuppression with anti-inflammatory drugs
- Antibody elimination therapies
- Systemic treatment of pemphigus (1)
- Systemic treatment of pemphigus (2)
- Clinical trials in pemphigus
- Clinical trial of sirolimus in pemphigus at UCI
- Drugs and drug targets in pemphigus
- Individualized immunosuppression
- Thank you
Topics Covered
- Pemphigus vulgaris (PV)
- PV is a life-long, life-threatening, IgG autoantibody-mediated blistering disease affecting oral/esophageal surfaces and/or skin. The fundamental myths hampered progress of pemphigus research toward development of a safe and efficient treatment. Elucidation of intimate mechanisms of keratinocyte detachment and death in pemphigus has challenged the monopathogenic explanation of disease focused of desmoglein autoimmunity. This chapter discusses recent advances of knowledge on PV, scrutinize old dogmas, resolve controversies and opens novel perspectives for treatment. PV is caused by a variety of autoantibodies that synergize with effectors of apoptotic and oncotic pathways, serine proteases, and inflammatory cytokines to overcome the natural resistance and activate the cell death program in keratinocytes. The concept of apoptolysis distinguishes the unique mechanism of autoantibody-induced keratinocyte damage in PV from other known forms of cell death. Although the optimal therapeutic strategy has not been established, the natural course of PV has improved due to a substantial progress in developing of the steroid-sparing therapies combining the immunosuppressive and direct anti-acantholytic effects. The ultimate goal pemphigus research
- Cure of patients by safe, non-toxic therapy
- Can be achieved through further elucidation of the molecular mechanisms mediating PV IgG-dependent keratinocyte detachment.
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Grando, S.A. (2014, May 4). The epidermis and blistering disorders: pemphigus [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 21, 2024, from https://doi.org/10.69645/CGSN7251.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Sergei A. Grando has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Clinical Practice
Transcript
Please wait while the transcript is being prepared...
0:00
The epidermis and
blistering disorders.
This lecture is on pemphigus.
0:07
Pemphigus vulgaris usually presents
on oral and genital mucosa,
and may also involve skin.
The lesions are fragile
bullae that lead
to shallow erosions
that heal very slowly.
Biopsy shows acantholytic
suprabasal cleft.
Direct immunofluorescence of biopsy
reveals epidermal deposits of IgG
and complement in the
intercerllular space.
Indirect immunofluorescence
of serum demonstrates
so-called "intercellular"
antibodies reacting with the cell
membrane of stratified
squamous epithelium.
0:44
Prior to the introduction
of an effective therapy
with oral coritcosteroids
in the 1950s,
the disease had a dismal natural
course, with approximately 50%
mortality rate at two years
and about 100% mortality rate
by five years after the
onset of the disease.
The mortality rate now
is estimated at about 5%,
and death is almost invariably
due to complications
of immunosuppressive therapy.
1:13
Prognosis of pemphigus.
Complete and
long-lasting remissions,
such as no evidence of the disease
and no systemic therapy required
for at least six months,
can occur in about 25%,
50%, and 75% of patients 2, 5,
and 10 years after diagnosis,
respectively.
Patients with mild or
moderate disease and diagnosis
are twice as likely to enter a
long-lasting, complete remission
than those with severe disease.
Patients who respond
rapidly to treatment
are over twice as likely to enter
a long-lasting, complete remission
than those with a slower response.
If not promptly and
aggressively treated,
pemphigus hardens, providing the
opportunity for the spreading
of epitopes and rendering the
disease significantly
more difficult to control.